Manager TitleAgeSince
President - 14/12/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 14/12/2023
Director/Board Member - 14/12/2023
Date Insider Type Main position Quantity % Market Cap.
12/14/23 A Issuer sale

Director

127,934 0.0678%
12/14/23 A Issuer sale

Chief Executive Officer

643,595 0.3411%
12/14/23 A Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
+1.17%+1.09%+4.03%+15.90% 48.72B
-1.28%+2.71%+463.29%+577.27% 43.99B
-0.93%+7.90%+15.72%+74.33% 40.82B
-0.59%+3.15%+26.03%+8.92% 39.79B
0.00%+6.15%+23.03%+48.00% 32.7B
-1.54%0.00%+25.00%+120.24% 16.66B
-3.15%-1.05% - - 16.84B
+0.72%+0.31%+4.94%+21.57% 13.95B
-1.52%+5.94%+81.46%+29.68% 13.58B
Average -0.70%+3.71%+80.44%+111.99% 29.67B
Weighted average by Cap. -0.46%+3.66%+98.32%+135.24%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock